Objective To explore the relationship between the level of fibrinogen-albumin ratio (FAR) and left ventricular hypertrophy (LVH) in patients with chronic kidney disease (CKD) stage 3-5 and examine the related factors of LVH.

Methods  For this cross-sectional survey, general profiles and biochemical parameters were collected from 181 patients with CKD stages 3-5 treated from July 2018 to March 2020. Coronary Agatston score and left ventricular mass index (LVMI) were calculated. They were divided into two groups of left ventricular hypertrophy (LVH) and non-hypertrophy (non-LVH) for assessing risk factors for LVH.

Results  FAR level was higher in LVH group than non-LVH group 97.65(73.31, 143.29) vs 84.40(67.52,107.06), P=0.003; LV mass index was correlated positively with FAR level (r=0.194, P=0.010); High FAR level (OR=1.012, 95% CI: 1.003-1.020, P=0.006), history of hypertension (OR=5.348, 95%CI:1.634-17.499, P=0.006), valvular calcification (OR=3.392, 95%CI:1.490-7.722 P=0.004), coronary artery calcification (OR=2.675. 95%CI:1.180-6.064, P=0.018) and high blood uric acid level (OR=1.004, 95%CI:1.000-1.007, P=0.026) were independent risk factors for LV hypertrophy in patients with CKD stages 3-5. The area under the ROC curve for FAR prediction of LVH was 0.630 (P=0.003); lymphocyte count, blood uric acid, coronary calcification, valvular calcification, hypertension and FAR combined factors predicting the area under ROC curve for LVH was 0.833 (P<0.001).

Conclusions  As an independent risk factor for LVH in patients with CKD stage 3-5, FAR has some diagnostic and predictive values for patients with CKD stage 3-5 complicated with LVH.